Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
CytomX's EpCAM pivot does the job
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
More ROR1s enter the clinic
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Like Crest, Potomac succeeds up to a point
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
